机构:[1]Department of Urology, Peking University First Hospital, Beijing, China.[2]Institution of Urology, Peking University, Beijing, China.[3]Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China.[4]National Urological Cancer Center, Beijing, China.[5]Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.外科系统普通外科首都医科大学宣武医院[6]Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
第一作者机构:[1]Department of Urology, Peking University First Hospital, Beijing, China.[2]Institution of Urology, Peking University, Beijing, China.[3]Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China.[4]National Urological Cancer Center, Beijing, China.
通讯作者:
推荐引用方式(GB/T 7714):
Wu Tianyu,Ji Xing,Yun Yongyang,et al.SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway[J].Plos One.2025,20(10):e0333202.doi:10.1371/journal.pone.0333202.
APA:
Wu Tianyu,Ji Xing,Yun Yongyang,Wang Xiaofei,Gan Ying...&Zhang Qian.(2025).SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway.Plos One,20,(10)
MLA:
Wu Tianyu,et al."SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway".Plos One 20..10(2025):e0333202